211 related articles for article (PubMed ID: 33646304)
21. BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression.
Konkle BA; Walsh CE; Escobar MA; Josephson NC; Young G; von Drygalski A; McPhee SWJ; Samulski RJ; Bilic I; de la Rosa M; Reipert BM; Rottensteiner H; Scheiflinger F; Chapin JC; Ewenstein B; Monahan PE
Blood; 2021 Feb; 137(6):763-774. PubMed ID: 33067633
[TBL] [Abstract][Full Text] [Related]
22. Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice.
Annoni A; Cantore A; Della Valle P; Goudy K; Akbarpour M; Russo F; Bartolaccini S; D'Angelo A; Roncarolo MG; Naldini L
EMBO Mol Med; 2013 Nov; 5(11):1684-97. PubMed ID: 24106222
[TBL] [Abstract][Full Text] [Related]
23. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.
Niemeyer GP; Herzog RW; Mount J; Arruda VR; Tillson DM; Hathcock J; van Ginkel FW; High KA; Lothrop CD
Blood; 2009 Jan; 113(4):797-806. PubMed ID: 18957684
[TBL] [Abstract][Full Text] [Related]
24. Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice.
Gao C; Schroeder JA; Xue F; Jing W; Cai Y; Scheck A; Subramaniam S; Rao S; Weiler H; Czechowicz A; Shi Q
Blood Adv; 2019 Sep; 3(18):2700-2711. PubMed ID: 31515232
[TBL] [Abstract][Full Text] [Related]
25. Hyperactive piggyBac transposons for sustained and robust liver-targeted gene therapy.
Di Matteo M; Samara-Kuko E; Ward NJ; Waddington SN; McVey JH; Chuah MK; VandenDriessche T
Mol Ther; 2014 Sep; 22(9):1614-24. PubMed ID: 25034357
[TBL] [Abstract][Full Text] [Related]
26. Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application.
Monahan PE; Lothrop CD; Sun J; Hirsch ML; Kafri T; Kantor B; Sarkar R; Tillson DM; Elia JR; Samulski RJ
Mol Ther; 2010 Nov; 18(11):1907-16. PubMed ID: 20700109
[TBL] [Abstract][Full Text] [Related]
27. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy.
Mount JD; Herzog RW; Tillson DM; Goodman SA; Robinson N; McCleland ML; Bellinger D; Nichols TC; Arruda VR; Lothrop CD; High KA
Blood; 2002 Apr; 99(8):2670-6. PubMed ID: 11929752
[TBL] [Abstract][Full Text] [Related]
28. CRISPR-Mediated In Situ Introduction or Integration of
Tang Q; Hu Z; Zhao J; Zhou T; Tang S; Wang P; Xiao R; Chen Y; Wu L; Zhou M; Liang D
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240366
[TBL] [Abstract][Full Text] [Related]
29. CRISPR/Cas9-mediated in vivo gene targeting corrects hemostasis in newborn and adult factor IX-knockout mice.
Wang L; Yang Y; Breton CA; White J; Zhang J; Che Y; Saveliev A; McMenamin D; He Z; Latshaw C; Li M; Wilson JM
Blood; 2019 Jun; 133(26):2745-2752. PubMed ID: 30975639
[TBL] [Abstract][Full Text] [Related]
30. New and improved AAVenues: current status of hemophilia B gene therapy.
Brimble MA; Reiss UM; Nathwani AC; Davidoff AM
Expert Opin Biol Ther; 2016; 16(1):79-92. PubMed ID: 26524468
[TBL] [Abstract][Full Text] [Related]
31. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver.
Nathwani AC; Gray JT; Ng CY; Zhou J; Spence Y; Waddington SN; Tuddenham EG; Kemball-Cook G; McIntosh J; Boon-Spijker M; Mertens K; Davidoff AM
Blood; 2006 Apr; 107(7):2653-61. PubMed ID: 16322469
[TBL] [Abstract][Full Text] [Related]
32. A natural choice for hemophilia B.
Koeberl DD
Blood; 2015 Mar; 125(10):1509-10. PubMed ID: 25745178
[TBL] [Abstract][Full Text] [Related]
33. Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.
Samelson-Jones BJ; Finn JD; George LA; Camire RM; Arruda VR
JCI Insight; 2019 Jun; 5(14):. PubMed ID: 31219805
[TBL] [Abstract][Full Text] [Related]
34. Gene therapy for hemophilia: past, present and future.
George LA; Fogarty PF
Semin Hematol; 2016 Jan; 53(1):46-54. PubMed ID: 26805907
[TBL] [Abstract][Full Text] [Related]
35. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.
Wu Z; Sun J; Zhang T; Yin C; Yin F; Van Dyke T; Samulski RJ; Monahan PE
Mol Ther; 2008 Feb; 16(2):280-9. PubMed ID: 18059373
[TBL] [Abstract][Full Text] [Related]
36. Practical Implications of Factor IX Gene Transfer for Individuals with Hemophilia B: A Clinical Perspective.
Miesbach W; Sawyer EK
Hum Gene Ther Clin Dev; 2018 Jun; 29(2):80-89. PubMed ID: 29624465
[TBL] [Abstract][Full Text] [Related]
37. Integration-deficient lentiviral vectors expressing codon-optimized R338L human FIX restore normal hemostasis in Hemophilia B mice.
Suwanmanee T; Hu G; Gui T; Bartholomae CC; Kutschera I; von Kalle C; Schmidt M; Monahan PE; Kafri T
Mol Ther; 2014 Mar; 22(3):567-574. PubMed ID: 23941813
[TBL] [Abstract][Full Text] [Related]
38. Gene therapy for hemophilia B mice with scAAV8-LP1-hFIX.
Lu W; Zhou Q; Yang H; Wang H; Gu Y; Shen Q; Xue J; Dong X; Chen J
Front Med; 2016 Jun; 10(2):212-8. PubMed ID: 27052253
[TBL] [Abstract][Full Text] [Related]
39. Viral vector-mediated gene therapy for hemophilia.
VandenDriessche T; Collen D; Chuah MK
Curr Gene Ther; 2001 Sep; 1(3):301-15. PubMed ID: 12109144
[TBL] [Abstract][Full Text] [Related]
40. Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX.
Sun J; Hakobyan N; Valentino LA; Feldman BL; Samulski RJ; Monahan PE
Blood; 2008 Dec; 112(12):4532-41. PubMed ID: 18716130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]